AMD: Improving Vaccines
Vaccines have helped eliminate many diseases in the United States, such as polio, but other vaccine-preventable diseases, like whooping cough (pertussis), are rebounding. Using AMD technology, CDC scientists can find shifts in the DNA of circulating bacteria and viruses that help them evade vaccines. Through this work, we can develop more effective vaccines that shift with the changing microbes.
Vaccine-preventable diseases, such as measles, mumps, rubella, and polio, can easily mutate to evade vaccines. Investigators are using AMD technologies to develop a viral genomics pipeline (VGP) to better track the sources of outbreaks, in the United States and worldwide. VGP combines standardized laboratory methods with user-friendly computer analyses to detect previously unknown viruses faster and accelerate vaccine development and improvement. CDC is sharing the VGP with state public health laboratories to improve state capacity to respond to important disease threats.
Despite the availability of vaccines against pertussis (whooping cough), the disease has rebounded to between 10,000 and 50,000 reported cases in the United States each year since 2010. Using AMD technology, CDC scientists have found shifts in the DNA of circulating Bordetella pertussis bacteria that could be contributing to the resurgence of pertussis. One bacterial component targeted by the vaccine, pertactin, is a protein believed to help the bacteria attach to cells in the throat. However, researchers have confirmed that the types of B. pertussis that cause the most illness in the United States are missing pertactin. With AMD methods, investigators are mapping the complete genome of historical and currently circulating strains of B. pertussis to determine if these genetic changes are contributing to the reemergence of pertussis.
Developing the annual flu shot is a months-long process that involves surveillance and analysis of circulating flu strains, decisions by global influenza experts, isolation of needed strains, and the manufacture of the vaccines in time for flu season. However, during this process, circulating influenza strains can mutate, so that the vaccine is less effective than anticipated. With AMD technologies, CDC and its global partners are designing methods to reduce the time it takes to isolate circulating influenza strains.
By reducing the time between isolation and manufacturing the annual flu vaccine, the flu shot will more closely match circulating strains and be more effective during flu season.